Larimar Therapeutics, Inc.
LRMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $45 | $23 | $27 | $27 |
| G&A Expenses | $5 | $4 | $5 | $5 |
| SG&A Expenses | $5 | $4 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $49 | $28 | $31 | $31 |
| Operating Income | -$49 | -$28 | -$31 | -$31 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $2 | $2 |
| Pre-Tax Income | -$48 | -$26 | -$29 | -$29 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$48 | -$26 | -$29 | -$29 |
| % Margin | – | – | – | – |
| EPS | -0.61 | -0.41 | -0.46 | -0.45 |
| % Growth | -48.8% | 10.9% | -2.2% | – |
| EPS Diluted | -0.61 | -0.41 | -0.46 | -0.45 |
| Weighted Avg Shares Out | 78 | 64 | 64 | 64 |
| Weighted Avg Shares Out Dil | 78 | 64 | 64 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$48 | -$28 | -$31 | -$31 |
| % Margin | – | – | – | – |